Trimetazidine as adjunctive therapy for decreasing major adverse cardiac events in coronary artery disease patients undergoing reperfusion strategy: a meta-analysis of randomized controlled trials

Abstract Background Trimetazidine as adjunctive therapy in cardioischemic patients has shown improvement angina and left ventricular ejection fraction. Recent trials have conflicting evidence on its effect hard clinical outcomes. Purpose The objective of this meta-analysis is to compare the efficacy trimetazidine versus placebo reducing cardiac mortality major adverse events (MACE) coronary artery disease after reperfusion strategy. Methods A literature search was done using terms “coronary disease” OR “acute myocardial infarction” “stable pectoris” AND “percutaneous intervention” “thrombolysi” “reperfusion” “trimetazidine” “trimetazidine dihydrochloride” “randomized controlled trial”. We included who underwent percutaneous intervention or thrombolysis. Two reviewers independently applied eligibility criteria, assessed quality, extracted data. primary outcomes were combined events; secondary repeat revascularization, heart failure reperfusion, stent restenosis, recurrence angina, reinfarction. Risk ratios calculated for pooled data random effects fixed models. Results This study five involving a total 26,977 patients. comparison associated with lower MACE, but results not significant. Among outcomes, only restenosis significantly reduced (risk ratio, 0.53; 95% CI, 0.34–0.83; p=0.006). Conclusion does reduce mortality, failure, reinfarction reperfusion. However, it said population. Further should be conducted more standard dosing regimens, duration therapy, similar severities ischemic disease. Funding Acknowledgement Type funding sources: None.